WO2005063267A1 - Comprime oral desintegrable de feuilles de ginkgo - Google Patents
Comprime oral desintegrable de feuilles de ginkgo Download PDFInfo
- Publication number
- WO2005063267A1 WO2005063267A1 PCT/CN2004/001580 CN2004001580W WO2005063267A1 WO 2005063267 A1 WO2005063267 A1 WO 2005063267A1 CN 2004001580 W CN2004001580 W CN 2004001580W WO 2005063267 A1 WO2005063267 A1 WO 2005063267A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ginkgo biloba
- orally disintegrating
- disintegrating tablet
- extract
- tablet according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to a ginkgo biloba orally disintegrating tablet, which can be used to treat cardiovascular and cerebrovascular diseases, especially coronary heart disease, angina pectoris, acute cerebral infarction, and cerebral arterial stiffness or cerebral circulation disorders.
- the invention also relates to a method for preparing the ginkgo biloba orally disintegrating tablet. Background technique
- Ginkgo biloba is also known as Ginkgo biloba.
- Ginkgo biloba was first used in the Ming Dynasty. It was recorded for the treatment of lung deficiency, asthma, and heart diseases. At present, it is mostly used in the treatment of cardiovascular and cerebrovascular diseases, asthma, and peripheral blood vessels.
- most ginkgo biloba extracts have been used as raw materials, and modern formulation technologies have been used to make a variety of different dosage forms for the convenience of patients and medical workers.
- Ginkgo biloba extract (Extract of Ginkgo bi loba) has many chemical components.
- EGb mainly contains 24% flavonoid glycosides and 6% total lactones.
- flavonoid glycosides include quercetin, kaempferol and isorhamnetin; total lactones include ginkgolides A, B, C, M, J and ginkgolides.
- EGB also has 17 kinds of amino acids and trace elements such as Ca 2 ⁇ Mg 2 ⁇ P, Sr, Fe, and its pharmacological effects are as follows:
- Ginkgolides are natural PAF receptor antagonists in EGb. Among them, Ginkgolide B has the strongest activity. Dong Jingcheng et al. Demonstrated that the addition of platelet activating factor (PA) to platelet incubation solution can cause strong contraction of tracheal strips in vitro and reduce the number of P-adrenergic receptors in lung tissue. After pretreatment with ginkgolide, it can antagonize PAF This effect relaxes the bronchi and thus treats asthma. Fang Enwei and others found that blood PAF increased in gerbil bilateral carotid artery ligation ischemia-reperfusion injury model. Ginkgolide administration could significantly reduce blood PAF. Reduce ischemic brain damage, reduce infarct size, and reduce cerebral edema.
- EGB can increase the muscarinic choline receptors in the hippocampus of rats, and increase the renewal of norepinephrine in the rat cortex, which can improve and promote the efficacy of learning and memory.
- EGb and its lactones can also protect mouse neurons from glutamate damage, prevent glutamate-induced increase in Ca 2 + influx, and reverse the glutamate-induced hypothalamic arcuate neuron nucleus area ⁇ ⁇ Reduction.
- Ginkgo biloba extract has good effects in the treatment of many diseases.
- Cardiocerebral vascular disease Ginkgo biloba extract (EGb) has good effects on coronary heart disease and angina pectoris, hypertension, hypotension, and hyperlipidemia. It is mainly used in the treatment of cerebral vasospasm, senile cerebrovascular disease, senile dementia, and sequelae of traumatic brain injury. Clinical application has confirmed that its effective rate can reach more than 90%.
- Respiratory diseases Geng Zhiguang et al. Used Ginkgo biloba to treat 30 patients with asthma in remission. After treatment, compared with the control group, the airway hyperresponsiveness and lung function of the treatment group were significantly improved, and the difference was significant. It was confirmed that Ginkgo biloba extract can significantly reduce airway hyperresponsiveness in asthmatic patients and improve lung function. Asthma prevention has positive significance.
- Urinary system disease Ginkgo biloba extract can improve 1 cycle, reduce the infiltration of inflammatory cells, reduce the production of cytokines and improve kidney damage. According to reports, Yang Wenqing and other 31 patients with diabetic nephropathy treated with ginkgo biloba capsules confirmed that patients with blood glucose 24h urine protein, blood P2-MG, Bun, Cr and other indicators have improved significantly after treatment.
- ginkgolide B has enhanced the sensitivity of cancer cells to chemotherapeutic agents, can be used for the treatment of metastatic cancer, and has a certain effect on EB virus.
- EGb has a significant anti-deficient effect, and intermittent claudication for peripheral circulatory disorders also has therapeutic value [1] .
- oral solid immediate-release preparations have become a hot spot in the development of new drugs in recent years, especially orally disintegrating tablets, which have become the focus of tablet development due to their convenient taking, fast onset, high bioavailability, and good taste.
- Orally disintegrating tablets are tablets that do not require ice or require a small amount of water and do not need to chew. The tablets are placed on the tongue. After the saliva quickly dissolves or disintegrates, the medicine can be taken into the stomach by swallowing power. Orally disintegrating tablets are characterized by fast absorption, high bioavailability, less intestinal residues, and low side effects. Therefore, orally disintegrating tablets are suitable for drugs that require rapid onset of action and have a large difference between the effective concentration and the poisoning concentration.
- Injury and emergency medicines, non-steroidal anti-inflammatory drugs, antispasmodic and antiemetics, and analgesics are more suitable for making orally disintegrating tablets.
- some drugs, such as the blood concentration are relatively stable for a long time, which is prone to drug resistance. Orally disintegrating tablets can overcome this problem and produce a good therapeutic effect.
- Oral disintegrating tablets do not need to be fed with water.
- Saliva can disintegrate or dissolve them. They can be swallowed as ordinary tablets, or they can be taken after disintegration in water, or they can be taken without swallowing. In particular, it provides convenience for the elderly, children, those who have difficulty swallowing or who have difficulty in taking water. If certain methods are used to improve the taste during preparation, it can greatly improve the compliance of children with medication and solve the problem of difficult medication for infants and young children [4] .
- the purpose of the present invention is to make up for the shortcomings of the existing ginkgo biloba extract preparation technology, and provide a wide range of patients and medical workers with a fast absorption, high bioavailability, less intestinal residues, low side effects, and no need to drink water. It only takes tens of seconds to quickly disintegrate or dissolve. With the swallowing of saliva, the genital apricot leaf oral disintegration tablet and its preparation method can be completed to meet the growing needs in the medical field. Summary of the invention
- the present invention provides, in one aspect, a silver preparation leaf orally disintegrating tablet preparation, which comprises a ginkgo biloba extract and a filler, a disintegrant, a flavoring agent, a glidant, a lubricant, a scallion or a coating material, and Optional effervescent.
- the present invention provides a method for preparing orally disintegrating tablets. BRIEF DESCRIPTION OF THE DRAWINGS
- FIG. 1 is a schematic diagram showing the dissolution of the samples in Examples 1 to 4 using rutin as a dissolution evaluation index. detailed description
- the present invention provides a ginkgo biloba orally disintegrating tablet, which comprises the following ingredients:
- Emu or coating material 0-60%, 8. Effervescent 0 ⁇ 30%.
- the Ginkgo biloba extract used as a raw material is a raw material drug in the prior art, which is defined in the National Pharmacopoeia as follows: "This product is made from the dried leaves of the Ginkgo biloba plant Ginkgo bilobaL. "Extract", containing no less than 24.0% total brassinoside; no less than 6.0 ° / containing terpenoid lactones. .
- Ginkgo biloba extract may be used in the present invention are commercially available from numerous manufacturers or can be prepared by various known methods, including for example solvent extraction, supercritical C0 2 extraction method, extraction HSCCC, And cell and tissue culture synthesis methods (West China Journal of Pharmacy 2002, 17 (6): 437-439).
- the content of 4 Burgundy Apricot leaf extract is within 15 - 40% by weight, more preferably 20 - 35 wt 0 /
- the filler may be any type known in the art, including but not limited to mannitol (granular or powdered), xylitol, sorbitol, maltose, erythritol, microcrystalline cellulose, PR0S0LV® SMCC, polymeric sugar (EMDEX®), coupling sugar, glucose, lactose, sucrose, dextrin and starch, etc. They can be used alone or in any combination.
- the content of the filler in the apricot leaf orally disintegrating tablet of the present invention is preferably 20 to 60% by weight, and more preferably 35 to 60% by weight.
- the disintegrant can be of any type known in the art, including, for example, cross-linked polyvinyl pyrrolidone (PPVP), sodium carboxymethyl starch (CMS-Na), and low-substituted hydroxypropylmethyl fibers Any one of L-HPC, croscarmellose sodium (CCNa), or any combination thereof.
- the content of the disintegrant is preferably 5 to 25%, more preferably 10 to 20% by weight.
- the flavoring agent may be any type known in the art, including but not limited to mannitol, xylitol, stevioside, lactose, fructose, sucrose, proteose, maltitol, glycyrrhizin, Sodium cyclohexylsulfamate, gelatin, aspartam, banana flavor, pineapple flavor, vanillin, orange flavor, orange flavor, mint flavor, ginseng flavor, strawberry flavor, citric acid, pestic acid, etc. They can be used alone or in any combination.
- the content of the flavoring agent is preferably 0.5 to 30% by weight, and most preferably 0.5 to 10% by weight.
- the glidant may be of any type known in the art, including, for example, micronized silica gel, talc, Cab-0-sil, Arosil, 7j sodium aluminosilicate, or any combination thereof.
- the content of the glidant is preferably from 0.1 to 4% by weight, more preferably from 0.5 to 3%, and more preferably from 0.5 to 2.0%.
- the lubricant may be any type known in the art, including, for example, any one of magnesium stearate, magnesium dodecyl sulfate, talc, or the like, or Any combination of them.
- the content of the lubricant is preferably 0.5 to 2.8% by weight, and more preferably 1 to 2.5%.
- linden or coating material is an optional auxiliary material.
- They can be of any type known in the art, including, for example, gelatin, acacia, alginate, chitosan, carboxymethyl cellulose salts, cellulose acetate phthalate, ethyl cellulose, amidine fibers Cellulose, hypromellose, acrylic resin (domestic acrylic resins I, II, III, IV, Eudrag it® series), polyvinyl alcohol, polyvinylpyrrolidone, polyethylene glycol, etc., or any of them Any combination.
- the content of the sedge wood or the coating material is preferably 20 to 60% by weight, more preferably 30 to 60%, and most preferably 40 to 60%.
- an effervescent agent is also an optional adjuvant, and may be any type known in the art, including, for example, a mixture of citric acid or citric acid and sodium bicarbonate or sodium carbonate.
- the content of the effervescent agent is preferably 5 to 25% by weight, and more preferably 10 to 20%.
- the invention also relates to a method for preparing the ginkgo leaf extract orally disintegrating tablet, comprising the following steps: (1) weighing the flavoring agent with the ginkgo leaf extract or the taste-masked ginkgo leaf extract raw material particles according to the amount Take it and mix it for future use;
- the applied L apricot leaf extract can be directly mixed with a flavoring agent without treatment.
- the following pretreatment can be performed on the ginkgo leaf extract before mixing it with the flavoring agent to pre-mask the strong bitterness of the ginkgo leaf extract:
- micro-puppets cover the taste one by one, take the selected pupae, dissolve and dilute with distilled water To the appropriate concentration, such as 1-10w / v%, preferably 2-8w / v%, more preferably 3-5w / v%, and then add a glidant and mix it, and then suspend it with ginkgo leaf extract by vertical airflow The air suspension method is then used to prepare the micro centipede, and the obtained ginkgo biloba extract powder is coated with micro centipede granules and dried for later use; or
- Powder coating taste masking Take one by one the selected coating material, dissolve it with a suitable solvent such as ethanol, aqueous ethanol solution, acetone, etc., and dilute it to an appropriate concentration, such as 1-10w / v%, preferably 2- 8w / v%, more preferably 3-5w / v%, ready for use.
- a suitable solvent such as ethanol, aqueous ethanol solution, acetone, etc.
- concentration such as 1-10w / v%, preferably 2- 8w / v%, more preferably 3-5w / v%, ready for use.
- the ginkgo biloba extract was placed in an ebullating bed to boil, and then the solution was sprayed into the powder coating to obtain the ginkgo biloba extract powder coated particles, which were dried and sieved.
- the spray speed can be determined by conventional methods depending on the specific equipment used. These are all within the skill of those of ordinary skill in the art.
- the preparation method of the ginkgo biloba oral disintegrating tablet mentioned in the present invention is a direct compression method, which can be adopted by any manufacturer having a conventional tablet.
- the apricot leaf orally disintegrating tablet of the present invention can be used to treat diseases of the cardio-cerebral system, such as coronary heart disease, angina pectoris, acute cerebral infarction, and cerebral arteriosclerosis or cerebral circulation disorders.
- the dosage can be varied within a wide range according to the following known factors, such as: the type of disease to be treated, the severity of the disease, the weight of the patient, the route of administration chosen, and the number of administrations per day. However, the optimal amount can be easily and routinely determined by the clinician.
- pharmaceutical preparations in the prior art see for example "Remington Pharmaceutical Sciences, (1985)” or Remington: Pharmaceutical Sciences and Practice, 19th edition, 1995.
- the present invention relates to a method for treating, relieving or preventing a central brain system disease in an individual, such as coronary heart disease, angina pectoris, acute cerebral infarction, and cerebral arteriosclerosis or cerebral circulation disorder, etc., comprising administering to the individual an effective amount of the present invention Ginkgo biloba extract orally disintegrating tablet preparation.
- a central brain system disease such as coronary heart disease, angina pectoris, acute cerebral infarction, and cerebral arteriosclerosis or cerebral circulation disorder, etc.
- the term "individual” refers to any animal, preferably a mammal, especially a human, to which ginkgo biloba extract can be applied.
- Specific individuals for treatment include humans and non-human primates, sheep, horses, cows, goats, pigs, dogs, cats, rabbits, guinea pigs, hamsters, gerbils, rats, and rats.
- the total weight is 200g, made into a total of 1000 tablets, and the content of Ginkgo biloba extract is 20%.
- the first step is to take ginkgo biloba extract (Egb), aspartame and mint flavor, pass through a 40 mesh sieve, and mix well to obtain the flavored ginkgo biloba extract raw materials for use;
- the second step is to take microcrystalline cellulose, citric acid, sodium bicarbonate, mannitol, micronized silica gel, and cross-linked polyvinylpyrrolidone through a 40-mesh sieve, mix well, add the flavored raw materials and mix well, and finally add Magnesium stearate is not uniform;
- the third step is to measure the content of intermediates. After determining the tablet weight, send it to the tablet press to get the tablet.
- Example 2 Prefabricated micro-taste masking method
- gelatin and polyethylene glycol are mixed with water to make a certain concentration of solution, and then micronized silica gel is added and mixed.
- the second step is to take the ginkgo biloba extract and suspend it in a vertical air stream, and then prepare it by air suspension method.
- the obtained ginkgo biloba extract powder is coated with micro-granule particles, dried, and passed through a 0.5-leg sieve, ready for use;
- mannitol, micronized silica gel, croscarmellose sodium, stevioside and ginseng flavor are mixed and mixed, and then mixed with the sieved micro-sacrifice to make it uniform, and magnesium stearate is added to make it uniform;
- the fourth step is to detect the content of intermediates. After determining the tablet weight, send it to a tablet press to obtain tablets.
- Example 3 Taste masking by powder coating
- Raw materials ginkgo biloba extract 40g;
- the total weight is 200g, made into a total of 1000 tablets, and the content of Ginkgo biloba extract is 20%.
- ethyl cellulose, Eudrag it® E100 and Eudrag it® NE30D are dissolved with 95% ethanol and diluted to a certain concentration for later use;
- the ginkgo biloba extract was placed in an ebullating bed and boiled, and the solution was sprayed into the solution at a certain speed for powder coating to obtain ginkgo biloba extract powder-coated granules, which were dried and passed through a 0.6 mm sieve, and set aside.
- mannitol, micronized silica gel, cross-linked polyvinylpyrrolidone, aspartame and orange flavor are mixed and mixed, then mixed with the coated particles after sieving, and finally magnesium stearate is added and mixed.
- the fourth step is to detect the content of intermediates. After determining the tablet weight, send it to a tablet press to obtain tablets.
- Example 4 Taste masking by powder coating
- Raw materials ginkgo biloba extract 40g;
- Lubricant-magnesium stearate 2.5 g
- Binder-sodium carboxymethyl starch 2.0 g
- the first step Eudragit® E100, Eudrag it® NE 3 0D and ethyl cellulose are dissolved in an appropriate amount of ethanol and stirred well to dissolve. After adding 0.2% of the fine powder silica gel, keep stirring to evenly suspend the fine powder silica gel as Spade
- the second step is ginkgo biloba extract and 2% micronized silica gel: mix well, place in a fluidized bed, and prepare ⁇ by air suspension method;
- the third step is to prepare 5% glue slurry with sodium carboxymethyl starch with water as a binder.
- the fourth step is to mix the ginkgo biloba extract, citric acid and orange flavor through a 60-mesh sieve. Granulation, sieving through 40 mesh, drying, spare;
- mannitol is sieved through a 60 mesh sieve.
- the sixth step is to fully mix the ginkgo leaf extract particles and mannitol particles, add cross-linked polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, aspartam and micronized silica gel, mix well, and add stearic acid. Content to determine tablet weight;
- dissolution test method (Chinese Pharmacopoeia 2000 edition, Appendix XC, second method)
- 900 ml of hydrochloric acid solution (prepared by diluting 9 ml of concentrated hydrochloric acid to 100 ml) is used as a solvent, and the rotation speed is 50 revolutions per minute.
- the rotation speed is 50 revolutions per minute.
- Add the dissolution medium dilute 9ml concentrated hydrochloric acid to 1000ml hydrochloric acid solution) and dilute to the mark.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200310123852.1 | 2003-12-31 | ||
CNB2003101238521A CN1237981C (zh) | 2003-12-31 | 2003-12-31 | 银杏叶口腔崩解片及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005063267A1 true WO2005063267A1 (fr) | 2005-07-14 |
Family
ID=34338929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2004/001580 WO2005063267A1 (fr) | 2003-12-31 | 2004-12-30 | Comprime oral desintegrable de feuilles de ginkgo |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN1237981C (zh) |
WO (1) | WO2005063267A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111437245A (zh) * | 2020-03-30 | 2020-07-24 | 韶关学院 | 一种预防新型冠状病毒肺炎的金花茶l-茶氨酸口服剂及其制备方法和应用 |
EP4248955A3 (de) * | 2019-01-15 | 2023-11-22 | Dr. Willmar Schwabe GmbH & Co. KG | Verfahren zur herstellung von leicht einzunehmenden tabletten mit trockenextrakt aus ginkgo biloba blättern |
CN117530432A (zh) * | 2023-12-21 | 2024-02-09 | 东北农业大学 | 一种黑木耳冻干闪释片及其制备方法 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1250228C (zh) * | 2004-06-29 | 2006-04-12 | 北京科信必成医药科技发展有限公司 | 三七总皂苷口腔崩解片及其制备方法 |
CN100394917C (zh) * | 2005-09-21 | 2008-06-18 | 重庆康刻尔制药有限公司 | 银杏酮酯口腔崩解片及其制备方法 |
CN102138672A (zh) * | 2010-01-29 | 2011-08-03 | 刘勇 | 一种降脂保健品 |
CN108057027A (zh) * | 2018-01-22 | 2018-05-22 | 武汉维奥制药有限公司 | 格列美脲口腔崩解片及其制备方法 |
CN108853041A (zh) * | 2018-08-20 | 2018-11-23 | 益奇健康科技(上海)有限公司 | 一种口腔速崩片 |
CN111686088B (zh) * | 2020-07-03 | 2022-08-02 | 河北医科大学 | 一种包载银杏提取物的口腔速释片剂及其制备方法 |
CN112155209A (zh) * | 2020-09-11 | 2021-01-01 | 北京瑞草科技有限公司 | 黄酮含量高的银杏提取物微胶囊及其制备方法与应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1342067A (zh) * | 1999-03-01 | 2002-03-27 | 埃法尔姆公司 | 低易碎性的口服溶散片及其生产方法 |
CN1345554A (zh) * | 2000-09-26 | 2002-04-24 | 江苏板桥药业有限责任公司 | 银杏维生素c泡腾片 |
CN1383814A (zh) * | 2002-05-28 | 2002-12-11 | 沈阳东宇工业技术研究院有限公司 | 口腔速崩片及制备方法 |
CN1449756A (zh) * | 2003-04-30 | 2003-10-22 | 江西省药物研究所 | 盐酸地芬尼多口崩片制剂及其制法 |
CN1478467A (zh) * | 2003-06-28 | 2004-03-03 | 南昌弘益科技有限公司 | 口腔内快速崩解片剂及其制备方法 |
CN1502340A (zh) * | 2002-11-21 | 2004-06-09 | 成都尚科药业有限公司 | 银杏叶分散片制备方法 |
CN1528350A (zh) * | 2003-09-29 | 2004-09-15 | 武汉健民中药工程有限责任公司 | 一种含有银杏叶提取物的分散片 |
-
2003
- 2003-12-31 CN CNB2003101238521A patent/CN1237981C/zh not_active Expired - Lifetime
-
2004
- 2004-12-30 WO PCT/CN2004/001580 patent/WO2005063267A1/zh active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1342067A (zh) * | 1999-03-01 | 2002-03-27 | 埃法尔姆公司 | 低易碎性的口服溶散片及其生产方法 |
CN1345554A (zh) * | 2000-09-26 | 2002-04-24 | 江苏板桥药业有限责任公司 | 银杏维生素c泡腾片 |
CN1383814A (zh) * | 2002-05-28 | 2002-12-11 | 沈阳东宇工业技术研究院有限公司 | 口腔速崩片及制备方法 |
CN1502340A (zh) * | 2002-11-21 | 2004-06-09 | 成都尚科药业有限公司 | 银杏叶分散片制备方法 |
CN1449756A (zh) * | 2003-04-30 | 2003-10-22 | 江西省药物研究所 | 盐酸地芬尼多口崩片制剂及其制法 |
CN1478467A (zh) * | 2003-06-28 | 2004-03-03 | 南昌弘益科技有限公司 | 口腔内快速崩解片剂及其制备方法 |
CN1528350A (zh) * | 2003-09-29 | 2004-09-15 | 武汉健民中药工程有限责任公司 | 一种含有银杏叶提取物的分散片 |
Non-Patent Citations (1)
Title |
---|
YE. B. ET AL: "Preparation and Evaluation Quality of Folium Ginkgo Orally Disintegrating Tablets", NATURAL PRODUCT RESEARCH AND DEVELOPMENT, vol. 15, no. 4, 2003, pages 326 - 329 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4248955A3 (de) * | 2019-01-15 | 2023-11-22 | Dr. Willmar Schwabe GmbH & Co. KG | Verfahren zur herstellung von leicht einzunehmenden tabletten mit trockenextrakt aus ginkgo biloba blättern |
CN111437245A (zh) * | 2020-03-30 | 2020-07-24 | 韶关学院 | 一种预防新型冠状病毒肺炎的金花茶l-茶氨酸口服剂及其制备方法和应用 |
CN117530432A (zh) * | 2023-12-21 | 2024-02-09 | 东北农业大学 | 一种黑木耳冻干闪释片及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1555843A (zh) | 2004-12-22 |
CN1237981C (zh) | 2006-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4573397B2 (ja) | 速崩壊性固形製剤 | |
US8486450B2 (en) | Method of producing solid preparation disintegrating in the oral cavity | |
EP2263675A2 (en) | Pharmaceutical compositions of a neuroactive steroid and uses thereof | |
JP2009292843A (ja) | 固形製剤 | |
MX2011007399A (es) | Suspension farmaceutica de liberacion doble. | |
CN106511260B (zh) | 一种盐酸小檗碱口服微丸干凝胶及其制备方法和应用 | |
JP6166340B2 (ja) | フェンテルミン及びトピラマートを含む組み合わせ物、並びにその調製方法 | |
WO2005063267A1 (fr) | Comprime oral desintegrable de feuilles de ginkgo | |
JPH08169831A (ja) | 体内アルコール代謝促進剤及びその製造方法 | |
CN1046459A (zh) | 剂量形式的美贝维林 | |
TWI788557B (zh) | 穩定性優異的固態製劑 | |
JP5835875B2 (ja) | 口腔内速崩壊錠の製造方法 | |
JP2003034655A (ja) | 速崩壊性固形製剤 | |
EP1911444A1 (en) | Drug-containing coated fine particle for intrabuccally disintegrating preparation and method of producing the same | |
WO2006000137A1 (fr) | Comprime oral de notoginseng contenant de la saponine et procede de preparation | |
CN106822907B (zh) | 一种含消旋卡多曲的双相释放制剂及其制备方法 | |
JP2003081814A (ja) | 錠剤の製造方法 | |
CN106344519B (zh) | 一种坦度螺酮肠溶微丸及其制备方法和用途 | |
US7815939B2 (en) | Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms | |
EP3157516A1 (en) | Pharmaceutical compositions comprising ferric citrate and methods for the production thereof | |
CN106176659B (zh) | 一种坦度螺酮肠溶片及其制备方法 | |
WO2013139292A1 (zh) | 一种含辛弗林和托吡酯的联合产品 | |
CN101773546A (zh) | 丹参有效成分同步定位释药微丸及其制备方法 | |
CN106474080A (zh) | 一种孟鲁斯特纳口崩片及其制备方法 | |
JP2003290319A (ja) | 錠剤の製造装置 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC, DATED 06.12.2006. |
|
122 | Ep: pct application non-entry in european phase |